| Conditions: |
|
Leukemia - Unspecified Childhood Solid Tumor, Protocol Specific |
| Purpose: |
|
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in
treating young patients with relapsed or refractory solid tumors or leukemia.
|
| Study Summary: |
|
OBJECTIVES:
Primary
- Determine the maximum-tolerated dose (MTD) and recommended phase II dose of sorafenib
in pediatric patients with relapsed or refractory solid tumors.
- Determine whether pediatric patients with relapsed or refractory leukemia can tolerate
the MTD of sorafenib for solid tumors.
- Determine the tolerability, active N-oxide metabolite, pharmacodynamics, and activity
of sorafenib a the MTD in a subset of patients with acute myeloid leukemia (AML) and
FLT3-ITD mutation.
- Determine the toxicities of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
Secondary
- Determine, preliminarily, the antitumor activity of this drug within the confines of a
phase I trial.
- Assess the biologic effect of sorafenib on circulating endothelial cells (CEC),
circulating CEC precursors (CECP), VEGF, and VEGF-2 in peripheral blood.
- Assess the gene expression, proteomic profile, and ERK phosphorylation in blasts of
patients with refractory leukemia treated with this regimen.
- Assess the effect of sorafenib on solid tumor vascularity and tumor blood flow using
dynamic contrast-enhanced MRI (DEMRI) in patients with measurable soft tissue tumors.
- Analyze tumor samples and leukemic blasts for the presence of ras, raf, or FLT3
(leukemias) mutations.
- Analyze the plasma inhibitory activity for FLT3 phosphorylation in peripheral blood of
patients with AML and FLT3-ITD mutation.
- Determine the tolerability, pharmacokinetics of sorafenib and sorafenib's active
N-oxide metabolite, pharmacodynamics, and activity of sorafenib administered at the MTD
for refractory leukemias in a subset of patients with AML and FLT3-ITD mutation.
- Analyze the plasma inhibitory activity for FLT3 phosphorylation in peripheral blood
samples obtained at the time of PK studies in patients with FLT3-ITD mutation AML.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to
diagnosis (malignant solid tumor vs leukemia).
- Stratum 1 (refractory solid tumor patients): Patients receive oral sorafenib twice
daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence
of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of sorafenib until the maximum-tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
of 6 patients experience dose-limiting toxicity (DLT). Once the MTD is determined, up to 6
additional patients under 12 years of age may be treated at the MTD. The MTD dose level is
also expanded to enroll up to 6 patients with refractory leukemia.
- Stratum 2 (refractory leukemia patients): A cohort of 3-6 patients with leukemia
receives treatment as in stratum 1 at the MTD determined in stratum 1. If 2 of 3 or 2
of 6 patients experience a DLT at the solid tumor MTD, sorafenib is reduced by one dose
level. The leukemia MTD is defined as the dose at which < 1/3 of patients experience
DLT during course 1 of treatment.
- Stratum 3 (acute myeloid leukemia and FLT3-ITD mutation patients): Patients receive
sorafenib as in stratum 1 at the MTD determined in stratum 2.
Patients undergo blood sample collection for pharmacokinetics, pharmacodynamics (in leukemia
blasts only), circulating endothelial cells (CEC), circulating CEC precursors (CECP), VEGF
and VEGF-2 , gene expression, proteomic profile, ERK phosphorylation, and FLT3
phosphorylation activity. Tumor tissue samples may also be analyzed for the presence of ras,
raf, or FLT3.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 77 patients will be accrued for this study.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Diagnosis of 1 of the following:
- Histologically confirmed malignant solid tumor at original diagnosis or relapse
- Measurable or evaluable disease by CT scan or MRI
- Histologically confirmed leukemia, including 1 of the following:
- Acute lymphoblastic leukemia (ALL)
- Greater than 25% blasts in the bone marrow (M3 bone marrow)
- Acute myeloid leukemia (AML)
- Greater than 25% blasts in the bone marrow (M3 bone marrow)
- AML and FLT3-ITD mutation
- Patients must have ≥ 5% blasts in the bone marrow
- Active extramedullary disease (except leptomeningeal disease) allowed
- Juvenile myelomonocytic leukemia (JMML) meeting the following criteria:
- Peripheral blood monocytosis > 1,000/mm^3
- Blasts (including promonocytes) are < 20% of the WBCs in the blood and
of the nucleated bone marrow cells
- No Philadelphia chromosome (Ph) or BCR/ABL fusion gene
- Has ≥ 2 of the following additional diagnostic criteria:
- Hemoglobin F increased for age
- Immature granulocytes in the peripheral blood
- WBC > 10,000/mm^3
- Clonal chromosomal abnormality (e.g., may be monosomy 7)
- Sargramostim (GM-CSF) hypersensitivity of myeloid progenitors in
vitro
- Chronic myelogenous leukemia (CML) in blast crisis
- Greater than 25% blasts in the bone marrow (M3 bone marrow)
- Patients with Ph-positive CML must be refractory to imatinib mesylate
- Relapsed or refractory disease
- Patients with acute promyelocytic leukemia (APL) must be refractory to treatment
with tretinoin and arsenic trioxide
- Standard curative therapies or therapies proven to prolong survival with an
acceptable quality of life do not exist
- Active extramedullary disease, except active leptomeningeal leukemia, allowed
- No brain tumors or known brain metastases
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 50-100% (for patients > 10 years of age)
- Lansky PS 50-100% (for patients ≤ 10 years of age)
- Patients with solid tumors must have adequate bone marrow function, as defined by the
following:
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 75,000/mm^3 (transfusion independent)
- Hemoglobin ≥ 8.0 g/dL (red blood cell [RBC] transfusions allowed)
- Patients with leukemia may have abnormal blood counts but must meet the following
criteria:
- Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed)
- Hemoglobin ≥ 8.0 g/L (RBC transfusions allowed)
- Patients with acute myeloid leukemia and FLT3-ITD mutation
- Platelet count ≥ 20,000/mm^3
- Lipase and amylase normal
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR
creatinine normal based on age as follows:
- No greater than 0.8 mg/dL (for patients 5 years of age and under)
- No greater than 1.0 mg/dL (for patients 6-10 years of age)
- No greater than 1.2 mg/dL (for patients 11-15 years of age)
- No greater than 1.5 mg/dL (for patients over 15 years of age)
- Patients with solid tumors must meet the following criteria:
- Bilirubin normal for age
- ALT normal for age (for the purpose of this study, the upper limit of normal
[ULN] for ALT is 45 μ/L)
- Serum albumin ≥ 2 g/dL
- Patients with leukemia must meet the following criteria:
- Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times ULN for age
- ALT ≤ 5.0 times ULN for age (≤ 225 μ/L) (for the purpose of this study, the ULN
for ALT is 45 μ/L)
- Serum albumin ≥ 2 g/dL
- Albumin ≥ 2 g/dL
- PT, PTT, and INR normal (for patients on prophylactic anticoagulation)
- No evidence of dyspnea at rest
- No exercise intolerance
- Pulse oximetry > 94% on room air, if there is clinical indication for determination
- Diastolic blood pressure ≤ the 95th percentile for age and gender (height included
for AML and FLT3-ITD mutation patients)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled infection
- Able to swallow tablets
- No evidence of bleeding diathesis
- No other medical condition or situation that would preclude study compliance
- No known Gilbert syndrome
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy (for patients
with solid tumors)
- Recovered from the non-hematologic toxic effects of all prior therapy (for patients
with leukemia)
- Recovered from acute nonhematologic toxic effects of all prior anti-cancer
chemotherapy (for patients with AML and FLT3-ITD mutation)
- At least 7 days since prior hematopoietic growth factors
- At least 7 days since prior biologic agents
- At least 2 weeks since prior local palliative radiotherapy (small port)
- At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or
radiation to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiation (e.g., skull,
spine, pelvis, ribs)
- At least 3 months since prior stem cell transplantation or rescue (for patients with
solid tumors)
- No evidence of active graft-vs-host disease
- At least 3 months since prior myeloablative therapy followed by bone marrow or stem
cell transplantation (for patients with leukemia)
- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
(for patients with solid tumors)
- At least 24 hours since prior nitrosoureas (for patients with AML and FLT3-ITD
mutation)
- At least 2 weeks since prior chemotherapy (for patients with leukemia)
- At least 3 weeks since prior monoclonal antibody therapy
- No prior sorafenib
- No other concurrent investigational drugs
- No other concurrent anticancer agents or therapies, including chemotherapy,
radiotherapy, immunotherapy, or biologic therapy
- Concurrent maintenance-like chemotherapy for patients with AML and FLT3-ITD
mutation allowed
- No concurrent administration of any of the following:
- Cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin,
carbamazepine, or phenobarbital)
- Rifampin
- Grapefruit juice
- Hypericum perforatum (St. John wort)
- No concurrent therapeutic anticoagulation
- Concurrent prophylactic anticoagulation (e.g., low-dose warfarin) of venous or
arterial access devices allowed provided the requirements for PT, INR, or PTT
are met
|
| NCT ID: |
|
NCT00343694 |
| Primary Contact: |
|
Study Chair
Brigitte C. Widemann, MD
NCI - Pediatric Oncology Branch
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Boston, Massachusetts 02115
United States
Suzanne Shusterman
Phone: 617-632-4901
Site Status: Recruiting |